Pfizer Inc. and BioNTech SE asked U.S. regulators to authorize emergency use of their Covid-19 vaccine for children ages 5 to 11, a group for whom no shot is allowed, Pfizer said on Oct. 7.

Johnson & Johnson submitted data to the U.S. Food and Drug Administration for emergency use authorization of a booster shot of the company’s Covid-19 vaccine in people aged 18 and older.

Johnson & Johnson is expected to ask the U.S. Food and Drug Administration to authorize a booster for the company’s one-shot Covid-19 vaccine this week. In other news, President Biden’s chief medical advisor Dr. Anthony Fauci told CNBC that they expect the FDA to review data on Merck and Ridgeback Biotherapeutics’ new oral antiviral against Covid-19 “as quickly as they possibly can.”

A study out of Oxford University’s Leverhulme Centre for Demographic Science found that the Covid-19 pandemic has resulted in the largest drop in life expectancy in western Europe since World War II.

The U.S. Centers for Disease Control and Prevention (CDC) on Sept. 24 backed a booster shot of the Pfizer and BioNTech Covid-19 vaccine for Americans aged 65 and older, adults with underlying medical conditions and adults in high-risk working and institutional settings.

Initial results from a vaccine trial reported Sept. 20 showed that Pfizer and BioNTech’s Covid-19 vaccine might be safe for use in children under 12 years old. 

External advisors to the U.S. Food and Drug Administration will meet on Sept. 17 to consider data from Pfizer and BioNTech in support of booster shots. Meanwhile, a timeline is being presented on the authorization of Covid-19 vaccines for children.

An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) on Aug. 30 unanimously recommended the Pfizer Inc. and BioNTech SE Covid-19 vaccine for people age 16 and older, an important step that could help accelerate vaccine mandates in the United States.

Pfizer Inc. on Aug. 25 said a booster dose of the company’s two-shot Covid-19 vaccine spurs a more than threefold increase in antibodies against the coronavirus, as the drugmaker seeks U.S. regulatory approval for a third injection.

Pfizer Inc. and the company’s German partner BioNTech SE submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their Covid-19 vaccine, the drugmakers said on Aug. 16.